Local Trauma and Craniomaxillofacial Contract

Award

Cardiff and Vale University Health Board

Highlights

Award value
—
Winning supplier
Johnson & Johnson Medical Ltd
Award date
—

Details

Published
27 Oct 2026
Deadline
—
Value
—
Location
UKL22
Source
Find a Tender
Source notice ID
101577-2026
OCID
ocds-h6vhtk-0526ca
CPV codes
33184100
View on Find a Tender

Description

Cardiff and Vale University Health Board (CAV UHB) currently operates under a trauma and Craniomaxillofacial (CMF)

commitment agreement with Johnson & Johnson DePuy Synthes, designed to maintain continuity of supply, support clinician familiarity, and deliver cost efficiencies during the development of the Major Trauma Centre. This long standing partnership has provided operational stability over several years.

Similar opportunities

More from Cardiff and Vale University Health Board

View all

Lots (1)

LotTitleValue
1Cardiff and Vale University Health Board (CAVUHB) currently operates under a trauma commitment agreement with Johnson & Johnson DePuy Synthes. This longstanding partnership has been integral to supporting the organisation’s trauma services, ensuring continuity of supply, maintaining clinician familiarity with products, and delivering demonstrable cost efficiencies, particularly during the ongoing development of the Major Trauma Centre. As the Major Trauma Centre continues to evolve, stability wiCardiff and Vale University Health Board (CAVUHB) currently operates under a trauma commitment agreement with Johnson & Johnson DePuy Synthes. This longstanding partnership has been integral to supporting the organisation’s trauma services, ensuring continuity of supply, maintaining clinician familiarity with products, and delivering demonstrable cost efficiencies, particularly during the ongoing development of the Major Trauma Centre. As the Major Trauma Centre continues to evolve, stability within the supply chain remains essential. Retaining the incumbent supplier mitigates the risk of operational disruption and allows clinical and operational teams to focus on service transformation priorities rather than managing the risks associated with transitioning to a new provider. In addition, Johnson & Johnson DePuy Synthes has consistently demonstrated reliable performance, responsive support, and alignment with the Health Board’s service needs. This established and effective relationship provides confidence in the supplier’s ability to continue meeting clinical and operational requirements. In summary, extending the agreement for a further three years represents a balanced and strategic approach, ensuring clinical safety, financial efficiency, and operational continuity while supporting the ongoing development and optimisation of the Major Trauma Centre.—

Awarded contracts (1)

TitleSupplierValueAwarded
Award 101577-2026-CAV - (26-27) 48-1Johnson & Johnson Medical Ltd——